Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis
AuthorsCheok, K. P. L.
Kirkwood, A. A.
AffiliationDepartment of Hematology, University College London, London, UK.
MetadataShow full item record
CitationCheok KPL, Kirkwood AA, Menne T, Tholouli E, Chaganti S, Mathew A, et al. Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis. Leukemia & Lymphoma. Informa UK Limited; 2022. p. 1–5.
JournalLeukemia and Lymphoma
- Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
- Authors: Madduri D, Parekh S, Campbell TB, Neumann F, Petrocca F, Jagannath S
- Issue date: 2021 Feb 19
- Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
- Authors: Wu X, Wang L, Shen L, He L, Tang K
- Issue date: 2022 Jun 16
- Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy.
- Authors: Hong R, Zhao H, Wang Y, Chen Y, Cai H, Hu Y, Wei G, Huang H
- Issue date: 2021 Mar
- Prolonged SARS-CoV-2 Infection in a CAR T-Cell Therapy Recipient.
- Authors: Abbasi J
- Issue date: 2021 Mar 9
- State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
- Authors: Meir J, Abid MA, Abid MB
- Issue date: 2021 Dec